VIVS
VivoSim Labs, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.56
P/S
31.41
EV/EBITDA
-0.76
DCF Value
$6.01
FCF Yield
-238.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-8066.2%
Net Margin
-864.1%
ROE
-15.6%
ROA
-17.6%
ROIC
-228.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $26.0K | $-2.7M | $-1.84 |
| Q2 2026 | $28.0K | $-2.5M | $-1.74 |
| Q1 2026 | $37.0K | $-2.8M | $-1.94 |
| Q4 2025 | $51.0K | $6.9M | $4.68 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.44
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.